It’s a long-awaited win for Eli Lilly after donanemab faced several delays in its path to the market, including an initial rejection from the FDA last year.
More Stories
A new Blue Origin: CEO Dave Limp is bringing urgency and ‘decisiveness’ to Jeff Bezos’ space company
Dave Limp told CNBC that he only had one question for Jeff Bezos when he interviewed last year to become...
Coinbase to delist non-compliant EU stablecoins under new MiCA regulations
The EU’s MiCA was introduced in June, but won’t take effect until December Coinbase will deliver an update to its...
Zillow adds climate risk data to home listings as threats rise
More than 80% of buyers now consider climate risk when purchasing a home, according to a survey by Zillow.
Tiger Woods’ logo dispute with Tigeraire escalates with federal court filing
A logo dispute between Tiger Woods' apparel company Sun Day Red and Tigeraire is now in the hands of the...
Stellantis files federal lawsuit against UAW union over strike threats
Stellantis is suing the United Auto Workers, escalating a monthslong battle between the trans-Atlantic automaker and American union, CNBC has...
Mortgage rates spike after stronger-than-expected jobs report
The average rate on the 30-year fixed mortgage is now 6.53% according to Mortgage News Daily.